Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

ABBV-951 Maintains Stable Levodopa Exposure following Subcutaneous Infusion in Parkinson’s Disease Patients
Movement Disorders
P8 - Poster Session 8 (8:00 AM-9:00 AM)
3-017
Characterize levodopa pharmacokinetics (PK) and safety/tolerability of ABBV-951 in Parkinson’s disease (PD) patients following subcutaneous (SC) infusion.
As PD progresses, symptoms are no longer well controlled by oral medication due to a progressively narrower therapeutic window.  ABBV-951 is a new investigational drug being developed for the treatment of PD that provides continuous therapeutic levels of levodopa.  The current work characterizes the PK of ABBV-951 following continuous infusion in PD patients at different dose levels of ABBV-951.
ABBV-951 was administered via SC infusion to the abdomen of PD patients continuously for a total of 72 hours in an ongoing Phase 1 study.  Patients were stratified in 4 dose groups and received a fixed dose of ABBV-951 based on their daily LD dose intake.  Serial plasma PK samples were collected to assay for levodopa concentrations.  Safety and tolerability were assessed throughout the study.
Preliminary results from 13 subjects who completed the study showed that following ABBV-951 SC infusion, levodopa exposure remains stable with minimal fluctuation at steady state.  The levodopa fluctuation is similar to what has been previously reported in other ABBV-951 studies in healthy volunteers.  The range of levodopa exposures achieved in this study is consistent with what needed to control motor symptoms in advanced PD patients.  Four subjects (31%) reported adverse events (AE) that were considered to be possibly related to treatment.  The only adverse event which occurred in more than one subject was infusion site pain which occurred in 2 (15%) subjects.

ABBV-951 was able to deliver stable levodopa exposures in PD patients.
Authors/Disclosures
Matthew Rosebraugh, PhD (AbbVie)
PRESENTER 		Dr. Rosebraugh has received personal compensation for serving as an employee of AbbVie Inc. Dr. Rosebraugh has stock in AbbVie Inc..
No disclosure on file
Wei Liu Wei Liu has received personal compensation for serving as an employee of AbbVie. Wei Liu has received stock or an ownership interest from AbbVie.
Maurizio Facheris, MD, MSc (Vanqua Bio, Inc) Dr. Facheris has received personal compensation for serving as an employee of Vanqua Bio. Dr. Facheris has or had stock in Vanqua Bio.